Bioorg Med Chem Lett 25:40574064 Kazda CM, Ding Y, Kelly RP et al (2016) Evaluation of efficacy and safety of the glucagon receptor antagonist LY2409021 in patients with type 2 diabetes: 12- and 24-week phase 2 studies
Gemcitabine induces CAFs to secrete exosomes containing miR-3173-5p, which inhibits the expression of ACSL4, thereby decreasing PUFA binding to phospholipids and enhancing resistance to ferroptosis in PDAC cells [41, 42]
Of those who discontinue due to side effects, 73% do so during this window
This finding is valuable in demonstrating the importance of an effective dose when assessing the clinical effects of diet on disease
Consult with your doctor before starting any supplement, especially those marketed online
Obesity (Silver Spring) 2020;28:167886.PubMedPMC 46